<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1802244938
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Myteb
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TERIFLUNOMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2172.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Aizant Drug Research Solutions Pvt.Ltd&#x9;" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Aizant Drug Research Solutions Pvt.Ltd	
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA31
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Myteb<sup>&reg; </sup>is</strong></p><p><strong>Myteb<sup>&reg; </sup></strong>contains the active substance teriflunomide which is an immunomodulatory agent and adjusts the immune system to limit its attack on the nervous system.</p><p><strong>What Myteb<sup>&reg; </sup>is used for</strong></p><p><strong>Myteb<sup>&reg;</sup></strong> is used in adults to treat relapsing remitting multiple sclerosis (MS).</p><p><strong>What multiple sclerosis is</strong></p><p>MS is a long-term illness that affects the central nervous system (CNS). The CNS is made up of the brain and spinal cord. In multiple sclerosis, inflammation destroys the protective sheath (called myelin) around the nerves in the CNS. This loss of myelin is called demyelination. This stops nerves from working properly. People with relapsing form of multiple sclerosis will have repeated attacks (relapses) of physical symptoms caused by their nerves not working properly. These symptoms vary from patient to patient but usually involve:</p><p>&bull; Difficulty walking.</p><p>&bull; Vision problems.</p><p>&bull; Balance problems.</p><p>Symptoms may disappear completely after the relapse is over, but over time, some problems may remain between relapses. This can cause physical disabilities that may interfere with your daily activities.</p><p><strong>How Myteb<sup>&reg;</sup> works</strong></p><p><strong>Myteb<sup>&reg; </sup></strong>helps to protect against attacks on the central nervous system by the immune system by limiting the increase of some white blood cells (lymphocytes). This limits the inflammation that leads to nerve damage in MS.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take</strong> <strong>Myteb<sup>&reg;</sup>:</strong></p><p>If you are allergic to teriflunomide or any of the other ingredients of this medicine.</p><p>If you have severe liver problems.</p><p>If you are pregnant, think you may be pregnant, or are breast-feeding.</p><p>If you suffer from a serious problem which affects your immune system e.g. acquired immunodeficiency syndrome (AIDS).</p><p>If you have a serious problem with your bone marrow, or if you have low numbers of red or white cells in your blood or a reduced number of blood platelets.</p><p>If you are suffering from a serious infection.</p><p>If you have severe kidney problems which require dialysis.</p><p>If you have very low levels of proteins in your blood (hypoproteinaemia).</p><p>If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p><strong>Warnings and precautions</strong></p><p><strong>Talk to your doctor or pharmacist before taking Myteb<sup>&reg;</sup>:</strong></p><p>If you have liver problems, your doctor will carry out blood tests before and during treatment to check how well your liver is working. If your test results show a problem with your liver, your doctor may stop your treatment with <strong>Myteb<sup>&reg;</sup></strong>.</p><p>If you have high blood pressure (hypertension) whether it is controlled with medicines or not. <strong>Myteb<sup>&reg;</sup></strong> can cause an increase in blood pressure. Your doctor will check your blood pressure before the start of treatment and regularly thereafter.</p><p>If you have an infection. Before you take <strong>Myteb<sup>&reg;</sup></strong>, your doctor will make sure you have enough white blood cells and platelets in your blood. As <strong>Myteb<sup>&reg;</sup></strong> decreases the number of white cells in the blood this may affect your ability to fight the infection. Your doctor may do blood tests to check your white blood cells if you think you have an infection.</p><p>If you have severe skin reactions.</p><p>If you have respiratory symptoms.</p><p>If you have weakness, numbness and pain in the hands and feet.</p><p>If you are going to have a vaccination.</p><p>If you take leflunomide with <strong>Myteb<sup>&reg;</sup></strong>.</p><p>If you are switching to or from <strong>Myteb<sup>&reg;</sup></strong>.</p><p>If you are lactose intolerant.</p><p>If you are due to have a specific blood test (calcium level). Falsely low levels of calcium can be detected.</p><p><strong>Children and adolescents</strong></p><p><strong>Myteb<sup>&reg; </sup></strong>should not be used in children and adolescents under 18 years of age. This is because the effects of the medicine in this age group are not known.</p><p><strong>Other medicines and Myteb<sup>&reg;</sup></strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following:</p><p>Leflunomide, methotrexate and other medicines that affect the immune system (often called immunosuppressants or immunomodulators).</p><p>Rifampicin (a medicine used to treat tuberculosis and other infections).</p><p>Carbamazepine, phenobarbital, phenytoin for epilepsy.</p><p>St John&rsquo;s wort (a herbal medicine for depression).</p><p>Repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes.</p><p>Daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer.</p><p>Duloxetine for depression, urinary incontinence or in kidney disease in diabetics.</p><p>Alosetron for the management of severe diarrhea.</p><p>Theophylline for asthma.</p><p>Tizanidine, a muscle relaxant.</p><p>Warfarin, an anticoagulant used to make the blood thinner (i.e. more fluid) in order to avoid blood clots.</p><p>Oral contraceptives (containing ethinylestradiol and levonorgestrel).</p><p>Indometacin, ketoprofen for pain or inflammation.</p><p>Furosemide for heart disease.</p><p>Cimetidine for reducing gastric acid.</p><p>Zidovudine for HIV infection.</p><p>Rosuvastatin, simvastatin, atorvastatin, pravastatin for hypercholesterolemia (high cholesterol).</p><p>Sulfasalazine for inflammatory bowel disease or rheumatoid arthritis.</p><p>Cholestyramine for high cholesterol or relief from itching in liver disease.</p><p>Activated charcoal to reduce absorption of medicines or other substances.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Do not take <strong>Myteb<sup>&reg; </sup></strong>if you are, or think you may be pregnant. If you are pregnant or become pregnant while taking <strong>Myteb<sup>&reg;</sup></strong>, the risk of having a baby with birth defects is increased.</p><p>Women of childbearing potential must not take this medicine without using reliable contraceptive measures.</p><p>Tell your doctor if you plan to become pregnant after stopping treatment with <strong>Myteb<sup>&reg;</sup></strong>, as you need to ensure that most of this medicine has left your body before trying to become pregnant.</p><p>The elimination of the active substance may take up to 2 years to occur naturally. The time can be reduced to a few weeks by taking certain medicines which speed up removal of <strong>Myteb<sup>&reg; </sup></strong>from your body. In either case it should be confirmed by a blood test that the active substance has been sufficiently removed from your body and you need confirmation from your treating physician that the blood level of <strong>Myteb<sup>&reg; </sup></strong>is low enough to allow you to become pregnant.</p><p>For further information on the laboratory testing please contact your doctor.</p><p>If you suspect that you are pregnant while taking <strong>Myteb<sup>&reg; </sup></strong>or in the two years after you have stopped treatment, you must contact your doctor immediately for a pregnancy test. If the test confirms that you are pregnant, your doctor may suggest treatment with certain medicines to remove <strong>Myteb<sup>&reg; </sup></strong>rapidly and sufficiently from your body, as this may decrease the risk to your baby.</p><p><strong>Contraception</strong></p><p>You must use an effective method of contraception during and after treatment with <strong>Myteb<sup>&reg;</sup></strong>. Teriflunomide remains in your blood for a long time after you stop taking it. Continue to use effective contraception after you stop treatment.</p><p>Do this until the levels of <strong>Myteb<sup>&reg; </sup></strong>in your blood are low enough - Your doctor will check this.</p><p>Talk with your doctor about the best method of contraception for you and any potential need for contraception change.</p><p>Do not take <strong>Myteb<sup>&reg; </sup></strong>when you are breast-feeding, as teriflunomide passes into the breast milk.</p><p><strong>Driving and using machines</strong></p><p><strong>Myteb<sup>&reg;</sup></strong> might make you feel dizzy which may impair your ability to concentrate and react. If you are affected, do not drive or use machines.</p><p><strong>Myteb<sup>&reg; </sup>contains lactose</strong></p><p><strong>Myteb<sup>&reg; </sup></strong>contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p><strong>Myteb<sup>&reg; </sup>contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with <strong>Myteb<sup>&reg;</sup> </strong>will be overseen by a doctor who is experienced in the treatment of&nbsp;&nbsp; multiple sclerosis.</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>The recommended dose is one tablet (14 mg) daily.</p><p><strong>Route/method of administration</strong></p><p><strong>Myteb<sup>&reg; </sup></strong>is for oral use.</p><p><strong>Myteb<sup>&reg; </sup></strong>is taken every day as a single daily dose at any time of the day.</p><p>You should swallow the tablet whole with some water.</p><p><strong>Myteb<sup>&reg; </sup></strong>may be taken with or without food.</p><p><strong>If you take more Myteb<sup>&reg; </sup>than you should</strong></p><p>If you have taken too much <strong>Myteb<sup>&reg;</sup></strong>, call your doctor straight away. You may experience side effects similar to those described in section 4 below.</p><p><strong>If you forget to take Myteb<sup>&reg;</sup></strong></p><p>Do not take a double dose to make up for a forgotten tablet. Take your next dose at the scheduled time.</p><p><strong>If you stop taking Myteb<sup>&reg;</sup></strong></p><p>Do not stop taking <strong>Myteb<sup>&reg; </sup></strong>or change your dose without talking to your doctor first.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br /><strong>The following side effects may happen with this medicine.</strong></p><p><strong>Serious side effects</strong></p><p>Tell your doctor immediately,&nbsp;if you notice any of the following serious side effects:</p><p>Allergic reactions which might include symptoms of rash, hives, swelling of lips, tongue or face or sudden difficulty breathing.</p><p>Severe skin reactions which might include symptoms of skin rash, blistering, fever, or ulcers in your mouth.</p><p>Severe infections or sepsis (a potentially life-threatening type of infection) which might include symptoms of high fever, shaking, chills, reduced urine flow, or confusion.</p><p>Serious liver disease which might include symptoms of yellowing of your skin or the whites of your eyes, darker urine than normal, unexplained nausea and vomiting, or abdominal pain.</p><p>Inflammation of the lungs which might include symptoms of shortness of breath or persistent cough.</p><p>Inflammation of the pancreas which might include symptoms of severe pain in the upper abdominal area that may also be felt in your back, nausea, or vomiting.</p><p><strong>Other side effects can occur with the following frequencies</strong></p><p><strong>Very common (may affect more than 1 in 10 people):</strong></p><p>Headache.</p><p>Diarrhea, feeling sick.</p><p>Increase in ALT (increase in blood levels of certain hepatic enzymes) shown in tests.</p><p>Hair thinning</p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>Influenza, upper respiratory tract infection, urinary tract infection, bronchitis, sinusitis, sore throat and discomfort when swallowing, cystitis, gastroenteritis viral, oral herpes, tooth infection, laryngitis, fungal infection of the foot.</p><p>Laboratory values: a decrease in the number of red blood cells (anaemia), changes in liver and white blood cell test results, as well as elevations in a muscle enzyme (creatine phosphokinase) have been observed.</p><p>Mild allergic reactions.</p><p>Feeling anxious.</p><p>Pins and needles, feeling weak, numb, tingling or pain in the lower back or leg (sciatica); feeling numb, burning, tingling or pain in the hands and fingers (carpal tunnel syndrome).</p><p>Feeling your heartbeat.</p><p>Increase in blood pressure.</p><p>Being sick (vomiting), toothache, upper abdominal pain.</p><p>Rash, acne.</p><p>Pain of the tendons, joints, bones, muscle pain (musculoskeletal pain).</p><p>Needing to urinate more often than usual.</p><p>Heavy periods.</p><p>Pain.</p><p>Lack of energy or feeling weak (asthenia).</p><p>Weight loss.</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>Decrease in the number of blood platelets (mild thrombocytopenia).</p><p>Increased feeling or sensitivity, especially in the skin; stabbing or throbbing pain along one or more nerves, problems in the nerves of the arms or legs (peripheral neuropathy).</p><p>Nail disorders.</p><p>Post-traumatic pain.</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>Severe infections (including sepsis).</p><p>Severe allergic reactions (including anaphylaxis).</p><p>Pulmonary reaction (interstitial lung disease, ILD).</p><p>Inflammation of the liver, pancreas, or mouth/lips.</p><p>Severe skin reactions.</p><p>Abnormal levels of fats (lipids) in the blood.</p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Myteb<sup>&reg; </sup></strong>after the expiry date (EXP) which is stated on the blister and the carton.</p><p>The expiry date refers to the last day of that month.</p><p><strong>Myteb<sup>&reg;</sup></strong> Tablets: Store below 30&deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Myteb<sup>&reg;</sup> tablets contain</strong></p><p>&bull; The active substance is Teriflunomide.</p><p>&bull; The other ingredients are: Lactose monohydrate, maize starch, hydroxy propyl cellulose, microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, Opadry Yellow (HPMC 2910 / Hypromellose, Titanium Dioxide, Macrogol/ PEG, Iron oxide Yellow, Iron oxide Red).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Myteb® Tablets look like and contents of the pack

Myteb® 14mg tablets are Light yellow color round shaped biconvex film coated tablets debossed with “A” on one side and “14”on the other side, presented in Aluminum foil OPA/Alu/PVC blisters, intended for oral use.

Pack size: 28 Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Med City Pharma-KSA.</p><p>Tel: 00966920003288</p><p>Fax: 00966126358138</p><p>Mobile: 00966555786968</p><p>P.O .Box: 42512 - Jeddah 21551</p><p>E-mail: MD.admin@Axantia.com</p><p><strong>Manufactured by:</strong></p><p>Aizant Drug Research Solutions Pvt. Ltd., India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>مايتيب</strong><strong><sup>&reg;</sup></strong> على المادة الفعالة تيريفلونومايد وهي أحد العوامل المعدلة للمناعة والتي تعمل على ضبط جهاز المناعة للحد من هجومه على الجهاز العصبي.</p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>هي</strong><strong> </strong><strong>دواعي</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">يستعمل<strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong><strong> </strong>للبالغين لعلاج نوبات التصلب المتعدد الانتكاسية-المترددة.</p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>التصلب</strong><strong> </strong><strong>المتعدد</strong></p><p dir="RTL">التصلب المتعدد هو حالة طويلة الأمد تؤثر على الجهاز العصبي المركزي، الذي يتكون من الدماغ والحبل الشوكي. في حالة التهاب التصلب المتعدد يصيب التلف الغلاف الواقي (يسمى الميلين) المحيط بالأعصاب في الجهاز العصبي المركزي وبالتالي تتوقف الأعصاب عن العمل بشكل طبيعي. وهذا يسمى زوال الميلين.</p><p dir="RTL">الأشخاص الذين يعانون من الشكل الانتكاسي من التصلب المتعدد سوف يعانون من نوبات متكررة (انتكاسات) من الأعراض الجسدية الناتجة عن عدم قيام الأعصاب بعملها بالشكل الطبيعي. تختلف هذه الأعراض من مريض لآخر و لكنها تشترك عادة بحدوث ما يلي:</p><p dir="RTL">صعوبة في المشي.</p><p dir="RTL">مشاكل في الرؤية.</p><p dir="RTL">مشاكل في التوازن.</p><p dir="RTL">قد تختفي الأعراض كليا بعد انتهاء النوبة الانتكاسية، لكن مع الوقت، قد يستمر ظهور بعض المشاكل بين النوبات. وهذا قد يسبب إعاقات جسدية التي قد تتعارض مع الأنشطة اليومية.</p><p dir="RTL"><strong>طريقة</strong><strong> </strong><strong>عمل</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">يساعد <strong>مايتيب</strong><strong><sup>&reg;</sup></strong> في الوقاية من حدوث نوبات على الجهاز العصبي المركزي عن طريق جهاز المناعة وذلك عن طريق الحد من زيادة بعض خلايا الدم البيضاء (الخلايا الليمفاوية). وهذا يحد من الالتهاب الذي يؤدي إلى تلف الأعصاب في التصلب المتعدد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>تناول</strong> <strong>مايتيب</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">إذا كنت تعاني من تحسس لتيريفلونومايد أو لأي مكونات أخرى في هذا الدواء.</p><p dir="RTL">إذا كنت تعاني من مشاكل حادة في الكبد.</p><p dir="RTL">إذا كنت حامل، تعتقدين بأنك حامل، أو مرضعة.</p><p dir="RTL">إذا كنت تعاني من مشكلة خطيرة تؤثر على جهاز المناعة مثل متلازمة نقص المناعة المكتسبة.</p><p dir="RTL">إذا كنت تعاني من مشكلة خطيرة في نخاع العظم، أو إذا كنت تعاني من انخفاض في عدد خلايا الدم الحمراء أو البيضاء في الدم، أو قلة الصفيحات الدموية.</p><p dir="RTL">إذا كنت تعاني من التهاب خطير.</p><p dir="RTL">إذا كنت تعاني من مشاكل حادة في الكلى، التي تحتاج الخضوع للديلزة.</p><p dir="RTL">إذا كنت تعاني من انخفاض في مستويات البروتين في الدم بشكل كبير.</p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول هذا الدواء، إذا لم تكن متاكدا.</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>والمحاذير</strong></p><p dir="RTL"><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg; </sup></strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">إذا كنت تعاني من مشاكل في الكبد، سيقوم الطبيب بإجراء فحوصات دم قبل وخلال العلاج للتأكد من صحة عمل الكبد. إذا أظهرت النتائج وجود أي مشكلة في الكبد، قد يقوم الطبيب بإيقاف العلاج باستعمال <strong>مايتيب</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">إذا كنت تعاني من ارتفاع ضغط الدم سواء كان مسيطر عليه أم لا باستعمال الأدوية، قد يسبب <strong>مايتيب</strong><strong><sup>&reg;</sup></strong><strong> </strong>ارتفاع ضغط الدم. سيقوم الطبيب بمراقبة ضغط الدم قبل بدء العلاج و بشكل دوري بعد ذلك.</p><p dir="RTL">إذا كنت تعاني من التهاب. قبل تناول <strong>مايتيب</strong><strong><sup>&reg;</sup></strong><strong>،</strong><strong> </strong>سيتاكد الطبيب بأن مستوى خلايا الدم البيضاء و الصفيحات كاف في الدم. حيث أن <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>يقلل من عدد خلايا الدم البيضاء في الدم وهذا قد يؤثر على قدرتك على مقاومة الالتهاب. سيقوم الطبيب بإجراء فحوصات دم للتاكد من خلايا الدم البيضاء إذا كنت تعتقد بأنك تعاني من التهاب.</p><p dir="RTL">إذا كنت تعاني من تفاعلات حادة في الجلد.</p><p dir="RTL">إذا كنت تعاني من أعراض تنفسية.</p><p dir="RTL">إذا كنت تشعر بالضعف، تنميل و ألم في اليدين و القدمين.</p><p dir="RTL">إذا كنت ستأخذ مطعوم معين.</p><p dir="RTL">إذا كنت تتناول ليفلونومايد مع <strong>مايتيب</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">إذا كنت ستقوم بتغيير العلاج من أو إلى <strong>مايتيب</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">إذا كنت تعاني من عدم القدرة على تحمل اللاكتوز.</p><p dir="RTL">إذا كنت بحاجة للقيام بفحص دم محدد (مستوى الكالسيوم). قد تظهر نتيجة خاطئة لانخفاض&nbsp; مستويات الكالسيوم.</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>والمراهقون</strong></p><p dir="RTL">يجب عدم استعمال <strong>مايتيب</strong><strong><sup>&reg;</sup></strong> للأطفال و المراهقين الذين تقل أعمارهم عن 18 سنة، &nbsp;و???ذلك لأن آثار الدواء في هذه الفئة العمریة غیر معروفة.</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخرا أو من الممكن أن تتناول أي أدوية أخرى. هذا يتضمن الأدوية التي يتم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">بشكل خاص، أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:</p><p dir="RTL">ليفلونومايد، ميثوتركسيت والأدوية الأخرى التي تؤثر على جهاز المناعة (تسمى غالبا مثبطات المناعة أو معدلات المناعة).</p><p dir="RTL">ريفامبيسين (دواء يستعمل لعلاج السل و الالتهابات الأخرى).</p><p dir="RTL">كاربامازيبين، فينوباربيتال، فينيتوين لعلاج الصرع.</p><p dir="RTL">نبتة سانت جون (دواء عشبي لعلاج الاكتئاب).</p><p dir="RTL">رباجلينايد، بيوجليتازون، ناتيجلينايد أو روزجليتازون لعلاج داء السكري.</p><p dir="RTL">دونوروبيسين، دوكسوروبيسين، باكليتاكسيل، توبوتيكان لعلاج السرطان.</p><p dir="RTL">دولوكسيتين لعلاج الاكتئاب، سلس البول، أو في مرض الكلى عند مرضى داء السكري.</p><p dir="RTL">ألوسيترون للسيطرة على الإسهال الحاد.</p><p dir="RTL">ثيوفيلين لعلاج الربو.</p><p dir="RTL">تيزانيدين مرخي عضلات.</p><p dir="RTL">وارفارين، مضاد للتخثر يستعمل للوقاية من تجلط الدم.</p><p dir="RTL">وسائل منع الحمل التي يتم تناولها عن طريق الفم (المحتوية على ايثنايل إستراديول وليڤونورجيستريل).</p><p dir="RTL">إندوميتاسين، كيتوبروفين للألم و الالتهاب.</p><p dir="RTL">فيوروسيمايد لأمراض القلب.</p><p dir="RTL">سيميتيدين لتقليل حمض المعدة.</p><p dir="RTL">زيدوڤودين لعلاج التهاب نقص المناعة المكتسبة .</p><p dir="RTL">رزوڤاستاتين، سيمڤاستاتين، أتروڤاستاتين، براڤاستاتين لعلاج ارتفاع مستوى الكوليستيرول في الدم.</p><p dir="RTL">سلفاسالازين لعلاج مرض التهاب الأمعاء أو التهاب المفاصل الروماتيزمي.</p><p dir="RTL">كوليستيرامين لعلاج ارتفاع مستوى الكوليستيرول أو لتخفيف الحكة عند الإصابة بمرض في الكبد.</p><p dir="RTL">الفحم النشط لتقليل امتصاص الأدوية أو المواد الأخرى.</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">لا تتناولي <strong>مايتيب</strong><strong><sup>&reg;</sup></strong><strong> </strong>إذا كنت حامل أو تعتقدين بأنك حامل. إذا كنت حامل أو في حال حدوث الحمل خلال فترة تناول <strong>مايتيب</strong><strong><sup>&reg;</sup></strong>، يزداد خطر انجاب طفل مصاب بتشوهات خلقية.</p><p dir="RTL">يجب عدم تناول هذا الدواء من قبل النساء في سن الإنجاب بدون استعمال وسائل منع حمل موثوقة.</p><p dir="RTL">أخبري طبيبك إذا كنت تخططين للحمل بعد التوقف عن العلاج باستعمال <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>حيث تحتاجين إلى التأكد من أن معظم هذا الدواء قد خرج من الجسم قبل محاولة الحمل.</p><p dir="RTL">قد يستغرق التخلص من المادة الفعالة بشكل طبيعي سنتين أو أقل. من الممكن تقليل الوقت إلى أسابيع قليلة عن طريق تناول أدوية معينة والتي تسرع إخراج <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>من الجسم.</p><p dir="RTL">في كلا الحالتين يجب تأكيد خروج المادة الفعّالة من الجسم بشكل كاف عن طريق القيام بفحص الدم ويجب الحصول على تأكيد الطبيب المعالج بأن مستوى <strong>مايتيب</strong><strong><sup>&reg;</sup></strong> في الدم منخفض بما يكفي للسماح بالحمل.</p><p dir="RTL">الرجاء الاتصال مع الطبيب للمعلومات الإضافية عن الفحص المخبري.</p><p dir="RTL">إذا كنت تشكين بأنك حامل خلال فترة تناول <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>أو خلال سنتين بعد التوقف عن العلاج، يجب التوقف عن تناول <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>و الاتصال مع الطبيب فوراً لإجراء فحص الحمل.إذا أكد الفحص حدوث الحمل، قد يقترح الطبيب العلاج بأدوية معينة لإخراج <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>بسرعة و وبشكل كاف من الجسم، حيث قد يقلل هذا من تعرض طفلك للخطر.</p><p dir="RTL"><strong>منع</strong><strong> </strong><strong>الحمل</strong></p><p dir="RTL">يجب استعمال وسيلة فعالة لمنع الحمل خلال و بعد العلاج باستعمال <strong>مايتيب</strong><strong><sup>&reg;</sup></strong>. يبقى تيريفلونومايد في الجسم لفترة طويلة بعد التوقف عن تناوله. استمري في استعمال وسائل منع حمل فعالة بعد التوقف عن العلاج.</p><p dir="RTL">قومي بذلك الى أن تصبح مستويات <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>في الدم منخفضة بشكل كاف- سيقوم الطبيب بالتأكد من ذلك.</p><p dir="RTL">تحدثي مع طبيبك حول أفضل وسيلة لمنع الحمل بالنسبة لك، وأي حاجة محتملة لتغيير وسيلة منع الحمل.</p><p dir="RTL">لا تتناولي <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>إذا كنت مرضعة، حيث أنه يتم إفراز تيريفلونومايد في حليب الثدي.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">قد يجعلك <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>تشعر بالدوار و هذا يقد يضعف القدرة على التركيز و التفاعل. إذا حصل لديك ذلك، تجنب القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>على</strong><strong> </strong><strong>اللاكتوز</strong></p><p dir="RTL">يحتوي <strong>مايتيب</strong><strong><sup>&reg;</sup></strong> على اللاكتوز (نوع من السكريات). إذا أخبرت من قبل الطبيب بأنك تعاني من عدم القدرة على تحمل بعض أنواع السكريات، اتصل مع طبيبك قبل تناول هذا الدواء.</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مل مول من الصوديوم (23 ملغم) لكل قرص، أي يعتبر بشكل أساسي خال من الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيكون العلاج باستعمال <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>تحت إشراف الطبيب المتخصص في علاج التصلب المتعدد.</p><p dir="RTL">دائما تناول هذا الدواء تماما كما أخبرك طبيبك. تأكد من طبيبك إذا لم تكن متأكداً.</p><p dir="RTL">الجرعة الموصى بها هي قرص واحد (14 ملغم) يومياً.</p><p dir="RTL"><strong>طريقة</strong><strong> </strong><strong>الاستعمال</strong></p><p dir="RTL"><strong>مايتيب</strong><strong><sup>&reg; </sup></strong>مخصص للتناول عن طريق الفم.</p><p dir="RTL">يتم تناول <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>كل يوم<strong><sup> </sup></strong>كجرعة يومية مفردة في أي وقت من اليوم.</p><p dir="RTL">يجب تناول القرص كاملاً مع القليل من الماء.</p><p dir="RTL">من الممكن تناول <strong>مايتيب</strong><strong><sup>&reg;</sup></strong><strong> </strong>مع أو بدون تناول الطعام.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">إذا تناولت <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>أكثر مما يجب، اتصل مع طبيبك على الفور. قد تعاني من آثار جانبية مماثلة لتلك الموضحة في قسم رقم 4.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها. تناول جرعتك التالية في موعدها المحدد.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">لا تتوقف عن تناول <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>&nbsp;أو تغير الجرعة دون التحدث مع طبيبك أولاً.</p><p dir="RTL">إذا كان لديك أي اسئلة إضافية عن استعمال هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثار جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>الاثآر</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء</strong><strong>.</strong></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>خطيرة</strong></p><p dir="RTL">بعض الآثار الجانبية قد تكون أو قد تصبح خطيرة، إذا عانيت من أي منها، أخبر طبيبك فورا.</p><p dir="RTL">تفاعلات تحسسية التي قد تتضمن أعراض مثل طفح، شرى، تورم الشفاه، اللسان أو الوجه أو صعوبة مفاجئة في التنفس.</p><p dir="RTL">تفاعلات جلدية حادة التي قد تتضمن أعراض مثل طفح جلدي، تنفط، حمى، أو تقرحات في الفم.</p><p dir="RTL">التهابات حادة أو تعفن الدم (نوع من الالتهاب من المحتمل أن يهدد الحياة) و الذي قد يتضمن أعراض مثل حمى، ارتجاف، قشعريرة، انخفاض تدفق البول، أو ارتباك.</p><p dir="RTL">مرض خطير في الكبد يمكن الذي قد يتضمن أعراض مثل اصفرار الجلد أو المنطقة البيضاء في العيون، بول داكن اللون أكثر من المعتاد، شعور غير مفسر بالغثيان و قيء، أو ألم في البطن.</p><p dir="RTL">التهاب الرئتين الذي قد يتضمن أعراض مثل قصر النفس أو السعال المستمر.</p><p dir="RTL">التهاب البنكرياس الذي قد يتضمن أعراض مثل ألم في الجزء العلوي من البطن الذي يمكن أن تشعر به في الظهر، الشعور بالغثيان، أو قيء.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>حسب</strong><strong> </strong><strong>التكرارات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة</strong><strong> </strong><strong>جداً</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>):</strong></p><p dir="RTL">صداع.</p><p dir="RTL">إسهال، الشعور بالغثيان.</p><p dir="RTL">ارتفاع إنزيم ألانين ترانزأمينيز (ارتفاع مستوى إنزيمات الكبد في الدم) تظهر خلال الفحوصات.</p><p dir="RTL">ترقق الشعر</p><p dir="RTL"><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>او</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>):</strong></p><p dir="RTL">انفلونزا، التهاب الجهاز التنفسي العلوي، التهاب الجهاز البولي، التهاب الشعب الهوائية، التهاب الجيوب الأنفية، تقرح الحلق، شعور بعدم الراحة عند البلع، التهاب المثانة، التهاب المعدة و الأمعاء الڤيروسي، الحلأ الفموي، التهاب الأسنان، التهاب الحنجرة، التهاب فطري في القدم.</p><p dir="RTL">القيم المخبرية: لوحظ انخفاض في عدد خلايا الدم الحمراء (فقر الدم)، تغير في نتائج فحوصات خلايا الدم البيضاء و الكبد، وكذلك لوحظ ارتفاع في إنزيم العضلات (كرياتين فوسفوكاينيز).</p><p dir="RTL">تفاعلات تحسسية معتدلة.</p><p dir="RTL">الشعور بالقلق.</p><p dir="RTL">الإحساس بوخز خفيف، الشعور بالضعف، تنميل أو ألم أسفل الظهر أو الساق (عرق النسا)، شعور بالخدر، حرقة، تنميل أو ألم في اليدين والأصابع ( متلازمة النفق الرسغي).</p><p dir="RTL">الشعور بنبضات القلب.</p><p dir="RTL">ارتفاع ضغط الدم.</p><p dir="RTL">قيء، ألم في الأسنان، ألم في الجزء العلوي من البطن.</p><p dir="RTL">طفح، حب الشباب.</p><p dir="RTL">ألم في الأوتار، المفاصل، العظام، العضلات (ألم العضلات و العظام).</p><p dir="RTL">الحاجة إلى التبول أكثر من المعتاد.</p><p dir="RTL">حيض كثيف.</p><p dir="RTL">ألم.</p><p dir="RTL">قلة الطاقة أو الشعور بالضعف (وهن).</p><p dir="RTL">فقدان الوزن.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>أشخاص</strong><strong>):</strong></p><p dir="RTL">انخفاض في عدد الصفيحات الدموية (نقص الصفيحات الدموية المعتدل).</p><p dir="RTL">زيادة التحسس أو الإحساس، خصوصا في الجلد، ألم نابض أو طاعن على طول واحد أو أكثر من الأعصاب، مشاكل في أعصاب الذراعين أو الساقين (الاعتلال العصبي المحيطي).</p><p dir="RTL">اضطرابات في الأظافر.</p><p dir="RTL">ألم ما بعد الصدمة.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>معروفة</strong><strong> (</strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>):</strong></p><p dir="RTL">التهابات حادة (تتضمن تعفن الدم).</p><p dir="RTL">تفاعلات تحسسية حادة (تتضمن صدمة الحساسية).</p><p dir="RTL">تفاعلات رئوية (مرض رئوي خلالي).</p><p dir="RTL">التهاب الكبد، البنكرياس، أو الفم/الشفاه.</p><p dir="RTL">تفاعلات جلدية حادة.</p><p dir="RTL">مستويات غير طبيعية من الدهون في الدم.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>حصل</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية،</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong>. </strong><strong>هذا</strong><strong> </strong><strong>يتضمن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>مذكورة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستعمل <strong>مايتيب</strong><strong><sup>&reg; </sup></strong>بعد تاريخ انتهاء الصلاحية المذكورعلى الشريط، الملصق و العلبة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>مايتيب</strong><strong><sup>&reg;</sup></strong> أقراص: يحفظ في درجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا</strong><strong> </strong><strong>تحتوي</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">المادة الفعالة هي تيريفلونومايد.</p><p dir="RTL">المكونات الأخرى هي لاكتوز مونوهيدرات، نشا، ذرة، هيدروكسي بروبيل سيليولوز، ميكروكريستالين سيليلوز، نشا جلايكولات الصوديوم، ثاني أكسيد السيليكون الغروي، ستيرات المغنيسيوم، أوبادري أصفر (هيدروكسي بروبيل ميثيل سيليولوز/هيبروميلوز، ثاني أكسيد التيتانيوم، ماكروجول/بولي إيثيلين جلايكول، تلك، أكسيد الحديد الأصفر، أكسيد الحديد الأحمر).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف</strong><strong> </strong><strong>تبدو</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>و</strong><strong> </strong><strong>ما</strong><strong> </strong><strong>هي</strong><strong> </strong><strong>محتويات</strong><strong> </strong><strong>العلبة</strong></p><p dir="RTL"><strong>أقراص</strong><strong> </strong><strong>مايتيب</strong><strong><sup>&reg;</sup></strong><strong> 14 </strong><strong>ملغم</strong><strong>: </strong>أقراص مغلفة دائرية الشكل ذات لون أصفر فاتح، محدبة الوجهين، محفور على أحد الأوجه &ldquo;A&rdquo;، وعلى الوجه الآخر &ldquo;14&rdquo;، معبأة في أشرطة OPA/Alu/PVC، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 28 قرص مغلف.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مدينة الدواء للصناعات الدوائية- المملكة العربية السعودية.</p><p dir="RTL">الهاتف:&nbsp; 00966920003288</p><p dir="RTL">فاكس: 00966126358138</p><p dir="RTL">جوال: 00966555786968</p><p dir="RTL">ص.ب: 42512 &ndash; جدة 21551</p><p dir="RTL">البريد الإلكتروني: MD.admin@axantia.com</p><p dir="RTL"><strong>تصنيع</strong><strong>:</strong></p><p dir="RTL">أيزانت لحلول الأبحاث الدوائية الخاصة المحدودة، الهند.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Myteb® 14 mg Film Coated tablets.
Teriflunomide14 mg Film Coated Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 14 mg of teriflunomide.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.

Myteb® 14mg tablets are Light yellow color round shaped biconvex film coated tablets debossed with “A” on one side and “14”on the other side, presented in Aluminum foil OPA/Alu/PVC blisters, intended for oral use.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Myteb</strong><sup>&reg;</sup> is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The treatment should be initiated and supervised by a physician experienced in the management of multiple sclerosis.</p><p><strong><u>Posology</u></strong></p><p>The recommended dose of teriflunomide is 14 mg once daily.</p><p><strong><u>Special populations</u></strong></p><p><strong>Elderly population</strong></p><p><strong>Myteb<sup>&reg;</sup> </strong>should be used with caution in patients aged 65 years and over due to insufficient data on safety and efficacy.</p><p><strong>Renal impairment</strong></p><p>No dose adjustment is necessary for patients with mild, moderate or severe renal impairment not undergoing dialysis.</p><p>Patients with severe renal impairment undergoing dialysis were not evaluated. Teriflunomide is contraindicated in this population (see section 4.3).</p><p><strong>Hepatic impairment</strong></p><p>No dose adjustment is necessary for patients with mild and moderate hepatic impairment. Teriflunomide is contraindicated in patients with severe hepatic impairment (see section 4.3).</p><p><strong>Paediatric population &nbsp;</strong></p><p>The safety and efficacy of teriflunomide in children aged from 10 years to less than 18 years has not been established. There is no relevant use of teriflunomide in children aged from birth to less than 10 years for the treatment of multiple sclerosis.<br />No data are available.<br /><u>Method of administration</u></p><p>The film-coated tablets are for oral use. The tablets should be swallowed whole with some water.</p><p><strong>Myteb</strong><sup>&reg;</sup> can be taken with or without food.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Patients with severe hepatic impairment (Child-Pugh class C).
Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with teriflunomide and thereafter as long as its plasma levels are above 0.02 mg/l (see section 4.6). Pregnancy must be excluded before start of treatment (see section 4.6).
Breast-feeding women (see section 4.6).
Patients with severe immunodeficiency states, e.g. acquired immunodeficiency syndrome (AIDS).
Patients with significantly impaired bone marrow function or significant anaemia, leucopenia, neutropenia or thrombocytopenia.
Patients with severe active infection until resolution (see section 4.4).
Patients with severe renal impairment undergoing dialysis, because insufficient clinical experience is available in this patient group.
Patients with severe hypoproteinaemia, e.g. in nephrotic syndrome.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Monitoring</u></strong></p><p><strong>Before treatment</strong></p><p><strong>Before starting treatment with teriflunomide the following should be assessed:</strong></p><p>&bull; Blood pressure.</p><p>&bull; Alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT).</p><p>&bull; Complete blood cell count including differential white blood cell and platelet count.</p><p><strong>During treatment</strong></p><p><strong>During treatment with teriflunomide the following should be monitored:</strong></p><p>&bull; Blood pressure.</p><p><strong>-Check periodically.</strong></p><p>&bull; Alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT).</p><p>- Liver enzymes should be assessed at least every four weeks during the first 6 months of treatment and every 8 weeks thereafter or as indicated by clinical signs and symptoms such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine. For ALT (SGPT) elevations between 2- and 3-fold the upper limit of normal, monitoring must be performed weekly.</p><p>&bull; Complete blood cell counts should be performed based on clinical signs and symptoms (e.g. infections) during treatment.</p><p><strong><u>Accelerated elimination procedure</u></strong></p><p>Teriflunomide is eliminated slowly from the plasma. Without an accelerated elimination procedure, it takes an average of 8 months to reach plasma concentrations less than 0.02 mg/l, although due to individual variation in substance clearance it may take up to 2 years. An accelerated elimination procedure can be used at any time after discontinuation of teriflunomide (see sections 4.6 and 5.2 for procedural details).</p><p><strong><u>Hepatic effects</u></strong></p><p>Elevations of liver enzymes have been observed in patients receiving teriflunomide (see section 4.8). These elevations occurred mostly within the first 6 months of treatment.</p><p>Teriflunomide therapy should be discontinued if liver injury is suspected. consider discontinuing teriflunomide therapy if elevated liver enzymes (greater than 3-fold ULN) are confirmed. Patients with pre- existing liver disease may be at increased risk of developing elevated liver enzymes when taking teriflunomide and should be closely monitored for signals of liver disease.<br />The medicinal product should be used with caution in patients who consume substantial quantities of alcohol.<br /><strong><u>Hypoproteinaemia</u></strong></p><p>Since teriflunomide is highly protein bound and as the binding is dependent upon the concentrations of albumin, unbound plasma teriflunomide concentrations are expected to be increased in patients with hypoproteinaemia, e.g. in nephrotic syndrome. Teriflunomide should not be used in patients with conditions of severe hypoproteinaemia.</p><p><strong><u>Blood pressure</u></strong></p><p>Elevation of blood pressure may occur during treatment with teriflunomide (see section 4.8). Blood pressure must be checked before the start of teriflunomide treatment and periodically thereafter. Blood pressure elevation should be appropriately managed before and during treatment with teriflunomide.</p><p><strong><u>Infections</u></strong></p><p>Initiation of treatment with teriflunomide should be delayed in patients with severe active infection until resolution.</p><p>In placebo-controlled studies, no increase in serious infections was observed with teriflunomide (see section 4.8). However, based on the immunomodulatory effect of teriflunomide, if a patient develops a serious infection, suspending treatment with <strong>Myteb<sup>&reg;</sup> </strong>should be considered and the benefits and risks should be reassessed prior to re-initiation of therapy. Due to the prolonged half-life, accelerated elimination with cholestyramine or charcoal may be considered.</p><p>Patients receiving <strong>Myteb<sup>&reg;</sup> </strong>should be instructed to report symptoms of infections to a physician. Patients with active acute or chronic infections should not start treatment with <strong>Myteb<sup>&reg;</sup> </strong>until the infection(s) is resolved.</p><p>The safety of teriflunomide in individuals with latent tuberculosis infection is unknown, as tuberculosis screening was not systematically performed in clinical studies. Patients testing positive in tuberculosis screening, treat by standard medical practice prior to therapy with <strong>Myteb<sup>&reg;</sup></strong>.</p><p><strong><u>Respiratory reactions</u></strong></p><p>Interstitial lung disease (ILD) has been reported with teriflunomide in the post-marketing setting.</p><p>ILD and worsening of pre-existing ILD have been reported during treatment with leflunomide, the parent compound of teriflunomide. The risk is increased in patients who had a history of ILD when treated with leflunomide.</p><p>ILD may occur acutely at any time during therapy with a variable clinical presentation.</p><p>ILD may be fatal. New onset or worsening pulmonary symptoms, such as persistent cough and dyspnoea, may be a reason for discontinuation of the therapy and for further investigation, as appropriate. If discontinuation of the medicinal product is necessary, initiation of an accelerated elimination procedure should be considered.</p><p><strong><u>Haematological effects</u></strong></p><p>A mean decrease less than 15% from baseline affecting white blood cell count has been observed (see section 4.8). As a precaution, a recent complete blood cell count, including differential white blood cell count and platelets, should be available before the initiation of treatment with <strong>Myteb<sup>&reg;</sup></strong> and the complete blood cell count should be assessed during <strong>Myteb<sup>&reg; </sup></strong>therapy as indicated by clinical signs and symptoms (e.g., infections).</p><p>In patients with pre-existing anaemia, leucopenia, and /or thrombocytopenia as well as in patients with impaired bone marrow function or those at risk of bone marrow suppression, the risk of haematological disorders is increased. If such effects occur, the accelerated elimination&nbsp;procedure (see above) to reduce plasma levels of teriflunomide should be considered.</p><p>In cases of severe haematological reactions, including pancytopenia, <strong>Myteb<sup>&reg;</sup> </strong>and any concomitant myelosuppressive treatment must be discontinued and a teriflunomide accelerated elimination procedure should be considered.</p><p><strong><u>Skin reactions</u></strong></p><p>Cases of severe skin reactions have been reported postmarketing (including Stevens Johnson syndrome and toxic epidermal necrolysis).<br />In patients treated with leflunomide, the parent compound, very rare cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported.<br />In case of ulcerative stomatitis, teriflunomide administration should be discontinued. If skin and /or mucosal reactions are observed which raise the suspicion of severe generalised major skin reactions (Stevens-Johnson syndrome, or toxic epidermal necrolysis-Lyell&rsquo;s syndrome), teriflunomide and any other possibly associated treatment must be discontinued, and an accelerated procedure initiated immediately. In such cases patients should not be re-exposed to teriflunomide (see section 4.3).<br /><strong><u>Peripheral neuropathy</u></strong></p><p>Cases of peripheral neuropathy have been reported in patients receiving teriflunomide<strong> </strong>(see section 4.8). Most patients improved after discontinuation of teriflunomide. However, there was a wide variability in final outcome, i.e. in some patients the neuropathy resolved and some patients had persistent symptoms. If a patient taking <strong>Myteb<sup>&reg;</sup> </strong>develops a confirmed peripheral neuropathy, consider discontinuing <strong>Myteb<sup>&reg;</sup> </strong>therapy and performing the accelerated elimination procedure should be considered.</p><p><strong><u>Vaccination</u></strong></p><p>Two clinical studies have shown that vaccinations to inactivated neoantigen (first vaccination), or recall antigen (re-exposure) were safe and effective during teriflunomide<strong> </strong>treatment. The use of live attenuated vaccines may carry a risk of infections and should therefore be avoided.</p><p><strong><u>Immunosuppressive or immunomodulating therapies</u></strong></p><p>As leflunomide is the parent compound of teriflunomide, co-administration of teriflunomide with leflunomide is not recommended.</p><p>Co-administration with antineoplastic or immunosuppressive therapies used for treatment of MS has not been evaluated. Safety studies, in which teriflunomide was concomitantly administered with interferon beta or with glatiramer acetate for up to one year did not reveal any specific safety concerns, but a higher adverse reaction rate as compared to teriflunomide monotherapy was observed. The long term safety of these combinations in the treatment of multiple sclerosis has not been established.</p><p><strong><u>Switching to or from Myteb<sup>&reg;</sup></u></strong></p><p>Based on the clinical data related to concomitant administration of teriflunomide with interferon beta or with glatiramer acetate, no waiting period is required when initiating teriflunomide after interferon beta or glatiramer acetate or when starting interferon beta or glatiramer acetate, after teriflunomide.</p><p>Due to the long half-life of natalizumab, concomitant exposure, and thus concomitant immune effects, could occur for up to 2-3 months following discontinuation of natalizumab if <strong>Myteb<sup>&reg;</sup> </strong>was immediately started. Therefore, caution is required when switching patients from natalizumab to <strong>Myteb<sup>&reg;</sup></strong>.</p><p>Based on the half-life of fingolimod, a 6-week interval without therapy is needed for clearance from the circulation and a 1 to 2 month period is needed for lymphocytes to return to normal range following discontinuation of fingolimod. Starting <strong>Myteb<sup>&reg;</sup> </strong>during this interval will result in concomitant exposure to fingolimod. This may lead to an additive effect on the immune system and caution is, therefore, indicated.</p><p>In MS patients, the median t<sub>1/2z&nbsp;</sub>was approximately 19 days after repeated doses of 14 mg. If a decision is made to stop treatment with <strong>Myteb<sup>&reg;</sup></strong>, during the interval of 5 half-lives (approximately 3.5 months although may be longer in some patients), starting other therapies will result in concomitant exposure to <strong>Myteb<sup>&reg;</sup></strong>. This may lead to an additive effect on the immune system and caution is, therefore, indicated.</p><p><strong><u>Lactose</u></strong></p><p>Since <strong>Myteb<sup>&reg;</sup> </strong>tablets contain lactose, patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption, should not take this medicinal product.</p><p><strong><u>Interference with determination of ionised calcium levels</u></strong></p><p>The measurement of ionised calcium levels might show falsely decreased values under treatment with leflunomide and/or teriflunomide (the active metabolite of leflunomide) depending on the type of ionised calcium analyser used (e.g. blood gas analyser). Therefore, the plausibility of observed decreased ionised calcium levels needs to be questioned in patients under treatment with leflunomide or teriflunomide. In case of doubtful measurements, it is recommended to determine the total albumin adjusted serum calcium concentration.</p><p><strong><u>Sodium</u></strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet that is to say essentially &ldquo;sodium free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pharmacokinetic interactions of other substances on teriflunomide</u></strong></p><p>The primary biotransformation pathway for teriflunomide is hydrolysis, with oxidation being a minor pathway.</p><p><strong>Potent cytochrome P450 (CYP) and transporter inducers</strong></p><p>Co-administration of repeated doses (600 mg once daily for 22 days) of rifampicin (a CYP2B6, 2C8, 2C9, 2C19, 3A inducer), as well as an inducer of the efflux transporters P-glycoprotein [P-gp] and breast cancer resistant protein [BCRP] with teriflunomide (70 mg single dose) resulted in an approximately 40% decrease in teriflunomide exposure. Rifampicin and other known potent CYP and transporter inducers such as carbamazepine, phenobarbital, phenytoin and St John&#39;s Wort should be used with caution during the treatment with teriflunomide.</p><p><strong>Cholestyramine or activated charcoal</strong></p><p>It is recommended that patients receiving teriflunomide are not treated with cholestyramine or activated charcoal because this leads to a rapid and significant decrease in plasma concentration unless an accelerated elimination is desired. The mechanism is thought to be by interruption of enterohepatic recycling and/or gastrointestinal dialysis of teriflunomide.</p><p><strong><u>Pharmacokinetic interactions of teriflunomide on other substances</u></strong></p><p><strong>Effect of teriflunomide on CYP2C8 substrate: repaglinide</strong></p><p>There was an increase in mean repaglinide C<sub>max</sub>&nbsp;and AUC (1.7- and 2.4-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of CYP2C8&nbsp;in vivo. Therefore, medicinal products metabolised by CYP2C8, such as repaglinide, paclitaxel, pioglitazone or rosiglitazone, should be used with caution during treatment with teriflunomide.</p><p><strong>Effect of teriflunomide on oral contraceptives: 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel</strong></p><p>There was an increase in mean ethinylestradiol C<sub>max</sub>&nbsp;and AUC0-24&nbsp;(1.58- and 1.54-fold, respectively) and levonorgestrel C<sub>max</sub>&nbsp;and AUC0-24&nbsp;(1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide. While this interaction of teriflunomide is not expected to adversely impact the efficacy of oral contraceptives, it should be considered when selecting or adjusting oral contraceptive treatment used in combination with teriflunomide.</p><p><strong>Effect of teriflunomide on CYP1A2 substrate: caffeine</strong></p><p>Repeated doses of teriflunomide decreased mean C<sub>max</sub>&nbsp;and AUC of caffeine (CYP1A2 substrate) by 18% and 55%, respectively, suggesting that teriflunomide may be a weak inducer of CYP1A2&nbsp;in vivo. Therefore, medicinal products metabolised by CYP1A2 (such as duloxetin, alosetron, theophylline and tizanidine) should be used with caution during treatment with teriflunomide, as it could lead to the reduction of the efficacy of these medicinal products.</p><p><strong>Effect of teriflunomide on warfarin</strong></p><p>Repeated doses of teriflunomide had no effect on the pharmacokinetics of S-warfarin, indicating that teriflunomide is not an inhibitor or an inducer of CYP2C9. However, a 25% decrease in peak international normalised ratio (INR) was observed when teriflunomide was coadministered with warfarin as compared with warfarin alone. Therefore, when warfarin is co-administered with teriflunomide, close INR follow-up and monitoring is recommended.</p><p><strong>Effect of teriflunomide on organic anion transporter 3 (OAT3) substrates</strong></p><p>There was an increase in mean cefaclor C<sub>max</sub>&nbsp;and AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of OAT3&nbsp;in vivo. Therefore, when teriflunomide is coadministered with substrates of OAT3, such as cefaclor, benzylpenicillin, ciprofloxacin, indometacin, ketoprofen, furosemide, cimetidine, methotrexate, zidovudine, caution is recommended.</p><p><strong>Effect of teriflunomide on BCRP and /or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3) substrates.</strong></p><p>There was an increase in mean rosuvastatin C<sub>max</sub>&nbsp;and AUC (2.65- and 2.51-fold, respectively), following repeated doses of teriflunomide. However, there was no apparent impact of this increase in plasma rosuvastatin exposure on the HMG-CoA reductase activity. For rosuvastatin, a dose reduction by 50% is recommended for coadministration with teriflunomide. For other substrates of BCRP (e.g., methotrexate, topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-Co reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide, repaglinide, rifampicin) concomitant administration of teriflunomide should also be undertaken with caution. Patients should be closely monitored for signs and symptoms of excessive exposure to the medicinal products and reduction of the dose of these medicinal products should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Use in males</u></strong></p><p>The risk of male-mediated embryo-foetal toxicity through teriflunomide treatment is considered low (see section 5.3).</p><p><strong><u>Pregnancy</u></strong></p><p>There are limited amount of data from the use of teriflunomide in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Teriflunomide may cause serious birth defects when administered during pregnancy. Teriflunomide is contraindicated in pregnancy (see section 4.3).</p><p>Women of childbearing potential have to use effective contraception during treatment and after treatment as long as teriflunomide plasma concentration is above 0.02 mg/l. During this period women should discuss any plans to stop or change contraception with the treating physician. The patient must be advised that if there is any delay in onset of menses or any other reason to suspect pregnancy, they must notify the physician immediately for pregnancy testing, and if positive, the physician and patient must discuss the risk to the pregnancy. It is possible that rapidly lowering the blood level of teriflunomide, by instituting the accelerated elimination procedure described below, at the first delay of menses, may decrease the risk to the foetus.</p><p>For women receiving teriflunomide treatment, who wish to become pregnant, the medicinal product should be stopped and an accelerated elimination procedure is recommended in order to more rapidly achieve concentration below 0.02 mg/l (see below).</p><p>If an accelerated elimination procedure is not used, teriflunomide plasma levels can be expected to be above 0.02 mg/l for an average of 8 months, however, in some patients it may take up to 2 years to reach plasma concentration below 0.02 mg/l. Therefore, teriflunomide plasma concentrations should be measured before a woman begins to attempt to become pregnant. Once the teriflunomide plasma concentration is determined to be below 0.02 mg/l, the plasma concentration must be determined again after an interval of at least 14 days. If both plasma concentrations are below 0.02 mg/l, no risk to the foetus is to be expected.</p><p>For further information on the sample testing please contact the Marketing Authorisation Holder or its local representative (see section 7).</p><p><strong>Accelerated elimination procedure</strong></p><p><strong>After stopping treatment with teriflunomide:</strong></p><p>&bull; cholestyramine 8 g is administered 3 times daily for a period of 11 days, or cholestyramine 4 g three times a day can be used, if cholestyramine 8 g three times a day is not well tolerated.</p><p>&bull; Alternatively, 50 g of activated powdered charcoal is administered every 12 hours for a period of 11 days.</p><p>However, also following either of the accelerated elimination procedures, verification by 2 separate tests at an interval of at least 14 days and a waiting period of one-and-a-half months between the first occurrence of a plasma concentration below 0.02 mg/l and fertilisation is required.</p><p>Both cholestyramine and activated powdered charcoal may influence the absorption of oestrogens and progestogens such that reliable contraception with oral contraceptives may not be guaranteed during the accelerated elimination procedure with cholestyramine or activated powdered charcoal. Use of alternative contraceptive methods is recommended.</p><p><strong><u>Breast-feeding</u></strong></p><p>Animal studies have shown excretion of teriflunomide in milk. Teriflunomide is contraindicated during breast-feeding (see section 4.3).</p><p><strong><u>Fertility</u></strong></p><p>Results of studies in animals have not shown an effect on fertility (see section 5.3). Although human data are lacking, no effect on male and female fertility is anticipated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Myteb<sup>&reg;</sup></strong><sup> </sup>has no or negligible influence on the ability to drive and use machines.</p><p>In the case of adverse reactions such as dizziness, which has been reported with leflunomide, the parent compound, the patient&#39;s ability to concentrate and to react properly may be impaired. In such cases, patients should refrain from driving and using machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Summary of the safety profile</u></strong></p><p>A total of 2267 patients were exposed to teriflunomide (1155 on teriflunomide 7 mg and 1112 on teriflunomide 14 mg) once daily for a median duration of about 672 days in four placebo-controlled studies (1045 and 1002 patients for teriflunomide 7 mg and 14 mg, respectively) and one active comparator study (110 patients in each of the teriflunomide treatment groups) in patients with relapsing forms of MS (Relapsing Multiple Sclerosis, RMS).<br />Teriflunomide is the main metabolite of leflunomide. The safety profile of leflunomide in patients suffering fromrheumatoid arthritis or psoriatic arthritis may be pertinent when prescribing teriflunomide in MS patients.</p><p>The placebo-controlled pooled analysis was based on 2047 patients with Relapsing Multiple Sclerosis treated with teriflunomide once daily. Within this safety population, the most commonly reported adverse reactions in the teriflunomide treated patients were: headache, diarrhoea, increased ALT, nausea, and alopecia. In general, headache, diarrhoea, nausea and alopecia, were mild to moderate, transient and infrequently led to treatment discontinuation.</p><p><strong>Tabulated list of adverse reactions</strong></p><p>Adverse reactions reported with teriflunomide in placebo-controlled studies, reported for teriflunomide 7 mg or 14 mg at &ge; 1% higher rate than for placebo, are shown below. Frequencies were defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Influenza, Upper respiratory tract infection, Urinary tract infection, Bronchitis, Sinusitis, Pharyngitis, Cystitis, Gastroenteritis viral, Oral herpes, Tooth infection, Laryngitis, Tinea pedis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Severe infections including sepsis<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neutropenia<sup>b</sup>, Anaemia</p></td><td style="vertical-align:top"><p>Mild thrombocytopenia (platelets &lt;100G/l)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Mild allergic reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyper-sensitivity reactions (immediate or delayed) including anaphylaxis and angioedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Paraesthesia, Sciatica, Carpal tunnel syndrome</p></td><td style="vertical-align:top"><p>Hyperaesthesia, Neuralgia, Peripheral neuropathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interstitial lung disease</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea, Nausea</p></td><td style="vertical-align:top"><p>Abdominal pain upper, Vomiting, Toothache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis, Stomatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Alanine aminotransferase (ALT) increase<sup>b</sup></p></td><td style="vertical-align:top"><p>Gamma-glutamyltransferase (GGT) increase<sup>b</sup>, Aspartate aminotransferase increase<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute hepatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyslipidaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>Rash, Acne</p></td><td style="vertical-align:top"><p>Nail disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Severe skin reactionsa, Psoriasis (including pustular)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Musculoskeletal pain, Myalgia, Arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pollakiuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Menorrhagia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pain, Asthenia<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight decrease, Neutrophil count decrease<sup>b</sup>, White blood cell count decrease<sup>b</sup>, Blood creatine phosphokinase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Post-traumatic pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>a: please refer to the detailed description section b: see section 4.4<br /><strong>Description of selected adverse reactions</strong></p><p><strong>Alopecia</strong><br />Alopecia was reported as hair thinning, decreased hair density, hair loss, associated or not with hair texture change, in 13.9% of patients treated with 14 mg teriflunomide versus 5.1% in patients treated with placebo. Most cases were described as diffuse or generalised over the scalp (no complete hair loss reported) and occurred most often during the first 6 months and with resolution in 121 of 139 (87.1%) patients treated with<br />teriflunomide 14 mg. Discontinuation because of alopecia was 1.3% in the teriflunomide 14 mg teriflunomide group, versus 0.1% in the placebo group.</p><p><strong>Hepatic effects</strong></p><p>During placebo-controlled studies the following was detected:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>ALT increase (based on laboratory data) according to baseline status - Safety population in placebo-controlled studies</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=997)</strong></p></td><td style="vertical-align:top"><p><strong>Teriflunomide 14 mg</strong></p><p><strong>(N=1002)</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt;3 ULN</strong></p></td><td style="vertical-align:top"><p>66/994 (6.6%)</p></td><td style="vertical-align:top"><p>80/999 (8.0%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt;5 ULN</strong></p></td><td style="vertical-align:top"><p>37/994 (3.7%)</p></td><td style="vertical-align:top"><p>31/999 (3.1%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt;10 ULN</strong></p></td><td style="vertical-align:top"><p>16/994 (1.6%)</p></td><td style="vertical-align:top"><p>9/999 (0.9%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt;20 ULN</strong></p></td><td style="vertical-align:top"><p>4/994 (0.4%)</p></td><td style="vertical-align:top"><p>3/999 (0.3%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>ALT &gt;3 ULN and TBILI &gt;2 ULN</strong></p></td><td style="vertical-align:top"><p>5/994 (0.5%)</p></td><td style="vertical-align:top"><p>3/999 (0.3%)</p></td></tr></tbody></table><p>Mild increases in transaminase, ALT below or equal to 3-fold ULN were more frequently seen in teriflunomide-treated groups as compared to placebo. The frequency of elevations above 3-fold ULN and higher was balanced across treatment groups. These elevations in transaminase occurred mostly within the first 6 months of treatment and were reversible after treatment cessation. The recovery time varied between months and years.<br /><strong>Blood pressure effects</strong></p><p>In placebo-controlled studies the following was established:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systolic blood pressure was &gt;140 mm Hg in 19.9% of patients receiving 14 mg/day teriflunomide as compared to 15.5% receiving placebo.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systolic blood pressure was &gt;160 mm Hg in 3.8% of patients receiving 14 mg/day teriflunomide as compared to 2.0% receiving placebo.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diastolic blood pressure was &gt;90 mm Hg in 21.4% of patients receiving 14 mg/day teriflunomide as compared to 13.6% receiving placebo.</p><p><strong>Infections</strong><br />In placebo-controlled studies, no increase in serious infections was observed with teriflunomide 14 mg (2.7%) as compared to placebo (2.2%). Serious opportunistic infections occurred in 0.2% of each group.</p><p>Severe infections including sepsis, sometimes fatal have been reported postmarketing.<br /><strong>Haematological effects</strong></p><p>A mean decrease affecting white blood cell (WBC) count (&lt;15% from baseline levels, mainly neutrophil and lymphocytes decrease) was observed in placebo-controlled trials with teriflunomide, although a greater decrease was observed in some patients. The decrease in mean count from baseline occurred during the first 6 weeks then stabilised over time while on-treatment but at decreased levels (less than a 15% decrease from baseline). The effect on red blood cell (RBC) (&lt;2%) and platelet counts (&lt;10%) was less pronounced.<br /><strong>Peripheral neuropathy</strong></p><p>In placebo-controlled studies, peripheral neuropathy, including both polyneuropathy and mononeuropathy (e.g., carpal tunnel syndrome), was reported more frequently in patients taking teriflunomide than in patients taking placebo. In the pivotal, placebo-controlled studies, the incidence of peripheral neuropathy confirmed by nerve conduction studies was 1.9% (17 patients out of 898) on 14 mg of teriflunomide, compared with 0.4% (4 patients out of 898) on placebo. Treatment was discontinued in 5 patients with peripheral<br />neuropathy on teriflunomide 14 mg. Recovery following treatment discontinuation was reported in 4 of these patients.</p><p><strong>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</strong></p><p>There does not appear to be an increased risk of malignancy with teriflunomide in the clinical trial experience. The risk of malignancy, particularly lymphoproliferative disorders, is increased with use of some other agents that affect the immune system (class effect).<br /><strong>Severe skin reactions</strong></p><p>Cases of severe skin reactions have been reported with teriflunomide post-marketing (see section 4.4).</p><p><strong>Asthenia</strong><br />In placebo-controlled studies, frequencies for asthenia were 2.0%, 1.6% and 2.2% in the placebo, teriflunomide 7 mg and teriflunomide 14 mg group, respectively.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States:</strong></p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Symptoms</u></strong></p><p>There is no experience regarding teriflunomide overdose or intoxication in humans. Teriflunomide 70 mg daily was administered up to 14 days in healthy subjects. The adverse reactions were consistent with the safety profile for teriflunomide in MS patients.</p><p><strong><u>Management</u></strong></p><p>In the event of relevant overdose or toxicity, cholestyramine or activated charcoal is recommended to accelerate elimination. The recommended elimination procedure is cholestyramine 8 g three times a day for 11 days. If this is not well tolerated, cholestyramine 4 g three times a day for 11 days can be used. Alternatively, when cholestyramine is not available, activated charcoal 50 g twice a day for 11 days may also be used. In addition, if required for tolerability reasons, administration of cholestyramine or activated charcoal does not need to occur on consecutive days (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, Selective immunosuppressants, ATC Code: L04AA31</p><p><strong><u>Mechanism of action</u></strong></p><p>Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHO-DH), required for the de novo pyrimidine synthesis, As a consequence teriflunomide reduces the proliferation of dividing cells that need de novo synthesis of pyrimidine to expand. The exact mechanism by which teriflunomide exerts its therapeutic effect in MS is not fully understood, but this is mediated by a reduced number of lymphocytes.</p><p><strong><u>Pharmacodynamic effects</u></strong></p><p><strong>Immune system</strong></p><p>Effects on immune cell numbers in the blood: In the placebo-controlled studies, teriflunomide 14 mg once a day led to a mild mean reduction in lymphocyte count, of less than 0.3 x 10<sub>9</sub>/l, which occurred over the first 3 months of treatment and levels were maintained until the end of the treatment.</p><p><strong>Potential to prolong the QT interval</strong></p><p>In a placebo-controlled thorough QT study performed in healthy subjects, teriflunomide at mean steady-state concentrations did not show any potential for prolonging the QTcF interval compared with placebo: the largest time matched mean difference between teriflunomide and placebo was 3.45 ms with the upper bound of the 90% CI being 6.45 ms.</p><p><strong>Effect on renal tubular functions</strong></p><p>In the placebo-controlled studies, mean decreases in serum uric acid at a range of 20 to 30% were observed in patients treated with teriflunomide compared to placebo. Mean decrease in serum phosphorus was around 10% in the teriflunomide group compared to placebo. These effects are considered to be related to increase in renal tubular excretion and not related to changes in glomerular functions.</p><p><strong><u>Clinical efficacy and safety</u></strong></p><p>The efficacy of teriflunomide<sup> </sup>was demonstrated in two placebo-controlled studies, the TEMSO and the TOWER study, that evaluated once daily doses of teriflunomide 7 mg and 14 mg in adult patients with RMS.</p><p>A total of 1,088 patients with RMS were randomised in TEMSO to receive 7 mg (n=366) or 14 mg (n=359) of teriflunomide or placebo (n= 363) for 108 weeks duration. All patients had a definite diagnosis of MS (based on McDonald criteria (2001)), exhibited a relapsing clinical course, with or without progression, and experienced at least 1 relapse over the year preceding the trial or at least 2 relapses over the 2 years preceding the trial. At entry, patients had an Expanded Disability Status Scale (EDSS) score &le;5.5.</p><p>The mean age of the study population was 37.9 years. The majority of patients had relapsing&ndash;remitting multiple sclerosis (91.5%), but a subgroup of patients had secondary progressive (4.7%) or progressive relapsing multiple sclerosis (3.9%). The mean number of relapses within the year before study inclusion was 1.4 with 36.2% of patients having gadolinium-enhancing lesions at baseline. The median EDSS score at baseline was 2.50; 249 patients (22.9%) had an EDSS score &rsaquo; 3.5 at baseline. The mean duration of disease, since first symptoms, was 8.7 years. A majority of patients (73%) had not received disease-modifying therapy during the 2 years before study entry. The study results are shown in Table 1.</p><p>Long term follow-up results from TEMSO long term extension safety study (overall median treatment duration approximately 5 years, maximum treatment duration approximately 8.5 years) did not present any new or unexpected safety findings.</p><p>A total of 1,169 patients with RMS were randomised in TOWER to receive 7 mg (n=408) or 14 mg (n=372) of teriflunomide or placebo (n= 389) for a variable treatment duration ending at 48 weeks after last patient randomised. All patients had a definite diagnosis of MS (based on McDonald criteria (2005)), exhibited a relapsing clinical course, with or without progression, and experienced at least 1 relapse over the year preceding the trial or at least 2 relapses over the 2 years preceding the trial. At entry, patients had an Expanded Disability Status Scale (EDSS) score &le;5.5.</p><p>The mean age of the study population was 37.9 years. The majority of patients had relapsing&ndash;remitting multiple sclerosis (97.5%), but a subgroup of patients had secondary progressive (0.8%) or progressive relapsing multiple sclerosis (1.7%). The mean number of relapses within the year before study inclusion was 1.4. Gadolinium-enhancing lesions at baseline: no data. The median EDSS score at baseline was 2.50; 298 patients (25.5%) had an EDSS score &rsaquo; 3.5 at baseline. The mean duration of disease, since first symptoms, was 8.0 years. A majority of patients (67.2%) had not received disease-modifying therapy during the 2 years before study entry. The study results are shown in Table 1.</p><p>&nbsp;</p><p><strong>Table 1 - Main results (for the approved dose, ITT population)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td>&nbsp;</td><td colspan="2"><p><strong>TEMSO-study</strong></p></td><td colspan="2"><p><strong>TOWER-study</strong></p></td></tr><tr><td>&nbsp;</td><td><p><strong>Teriflunomide</strong></p><p><strong>14 mg</strong></p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>Teriflunomide</strong></p><p><strong>14 mg</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p>N</p></td><td><p><strong>358</strong></p></td><td><p><strong>363</strong></p></td><td><p><strong>370</strong></p></td><td><p><strong>388</strong></p></td></tr><tr><td><p><strong>Clinical Outcomes</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Annualised relapse rate</p></td><td><p>0.37</p></td><td><p>0.54</p></td><td><p>0.32</p></td><td><p>0.50</p></td></tr><tr><td><p><em>Risk difference (CI<sub>95%</sub>)</em></p></td><td colspan="2"><p>-0.17 (-0.26, -0.08)<sup>&lowast;&lowast;&lowast;</sup></p></td><td colspan="2"><p>-0.18 (-0.27, -0.09)<sup>&lowast;&lowast;&lowast;&lowast;</sup></p></td></tr><tr><td><p>Relapse-free&nbsp;<sub>week 108</sub></p></td><td><p>56.5%</p></td><td><p>45.6%</p></td><td><p>57.1%</p></td><td><p>46.8%</p></td></tr><tr><td><p>Hazard ratio (CI95%)</p></td><td colspan="2"><p>0.72, (0.58, 0.89)<sup>&lowast;&lowast;</sup></p></td><td colspan="2"><p>0.63, (0.50, 0.79)<sup>&lowast;&lowast;&lowast;&lowast;</sup></p></td></tr><tr><td><p>3-month Sustained Disability Progression&nbsp;<sub>week 108</sub></p></td><td><p>20.2%</p></td><td><p>27.3%</p></td><td><p>15.8%</p></td><td><p>19.7%</p></td></tr><tr><td><p><em>Hazard ratio (CI<sub>95%</sub>)</em></p></td><td colspan="2"><p>0.70 (0.51, 0.97)<sup>&lowast;</sup></p></td><td colspan="2"><p>0.68 (0.47, 1.00)<sup>&lowast;</sup></p></td></tr><tr><td><p>6-month Sustained Disability Progression&nbsp;<sub>week 108</sub></p></td><td><p>13.8%</p></td><td><p>18.7%</p></td><td><p>11.7%</p></td><td><p>11.9%</p></td></tr><tr><td><p><em>Hazard ratio (CI<sub>95%</sub>)</em></p></td><td colspan="2"><p>0.75 (0.50, 1.11)</p></td><td colspan="2"><p>0.84 (0.53, 1.33)</p></td></tr><tr><td><p><strong>MRI endpoints</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2" rowspan="7"><p>Not measured</p></td></tr><tr><td><p>Change in BOD&nbsp;<sub>week 108</sub><sup>(1)</sup></p></td><td><p>0.72</p></td><td><p>2.21</p></td></tr><tr><td><p><em>Change relative to placebo</em></p></td><td colspan="2"><p>67%<sup>&lowast;&lowast;&lowast;</sup></p></td></tr><tr><td><p>Mean Number of Gd-enhancing lesions at week 108</p></td><td><p>0.38</p></td><td><p>1.18</p></td></tr><tr><td><p><em>Change relative to placebo (CI<sub>95%</sub>)</em></p></td><td colspan="2"><p>-0.80 (-1.20, -0.39)<sup>&lowast;&lowast;&lowast;&lowast;</sup></p></td></tr><tr><td><p>Number of unique active lesions /scan</p></td><td><p>0.75</p></td><td><p>2.46</p></td></tr><tr><td><p><em>Change relative to placebo (CI<sub>95%</sub>)</em></p></td><td colspan="2"><p>69%, (59%; 77%)<sup>&lowast;&lowast;&lowast;&lowast;</sup></p></td></tr></tbody></table><p><sup>&lowast;</sup><sup> </sup><sup>&lowast;</sup><sup> </sup><sup>&lowast;</sup><sup> </sup><sup>&lowast;</sup><sup>&nbsp;</sup>p&lt;0.0001&nbsp;<sup>&lowast;&lowast;&lowast;</sup>&nbsp;p&lt;0.001&nbsp;<sup>&lowast;&lowast;</sup>&nbsp;p&lt;0.01&nbsp;<sup>&lowast;</sup>&nbsp;p&lt;0.05 compared to placebo</p><p>(1) BOD: burden of disease: total lesion volume (T2 and T1 hypointense) in ml</p><p><strong>Efficacy in patients with high disease activity:</strong></p><p>A consistent treatment effect on relapses and time to 3-month sustained disability progression in a subgroup of patients in TEMSO (n= 127) with high disease activity was observed. Due to the design of the study, high disease activity was defined as 2 or more relapses in one year, and with one or more Gd-enhancing lesion on brain MRI. No similar subgroup analysis was performed in TOWER as no MRI data were obtained.</p><p>No data are available in patients who have failed to respond to a full and adequate course (normally at least one year of treatment) of beta-interferon, having had at least 1 relapse in the previous year while on therapy, and at least 9 T2-hyperintense lesions in cranial MRI or at least 1 Gd-enhancing lesion, or patients having an unchanged or increased relapse rate in the prior year as compared to the previous 2 years.</p><p>TOPIC was a double-blind, placebo-controlled study that evaluated once daily doses of teriflunomide 7 mg and 14 mg for up to 108 weeks in patients with first clinical demyelinating event (mean age 32.1 years). The primary endpoint was time to a second clinical episode (relapse). A total of 618 patients were randomised to receive 7 mg (n=205) or 14 mg (n=216) of teriflunomide or placebo (n=197). The risk of a second clinical attack over 2 years was 35.9% in the placebo group and 24.0% in the teriflunomide 14 mg treatment group (hazard ratio: 0.57, 95% confidence interval: 0.38 to 0.87, p=0.0087). The results from the TOPIC study confirmed the efficacy of teriflunomide in RRMS (including early RRMS with first clinical demyelinating event and MRI lesions disseminated in time and space).</p><p>Teriflunomide effectiveness was compared to that of a subcutaneous interferon beta-1a (at the recommended dose of 44 &micro;g three times a week) in 324 randomised patients in a study (TENERE) with minimum treatment duration of 48 weeks (maximum 114 weeks). The risk of failure (confirmed relapse or permanent treatment discontinuation which ever came first) was the primary endpoint. The number of patients with permanent treatment discontinuation in the teriflunomide 14 mg group was 22 out of 111 (19.8%), the reasons being adverse events (10.8%), lack of efficacy (3.6%), other reason (4.5%) and lost to follow-up (0.9%). The number of patients with permanent treatment discontinuation in the subcutaneous interferon beta-1a group was 30 out of 104 (28 .8%), the reasons being adverse events (21.2%), lack of efficacy (1.9%), other reason (4.8%) and poor compliance to protocol (1%). Teriflunomide 14 mg/day was not superior to interferon beta-1a on the primary endpoint: the estimated percentage of patients with treatment failure at 96 weeks using the Kaplan-Meier method was 41.1% versus 44.4% (teriflunomide 14 mg versus interferon beta-1a group, p=0.595).</p><p><strong><u>Paediatric population</u></strong></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with teriflunomide in children from birth to less than 10 years in treatment of multiple sclerosis (see section 4.2 for information on paediatric use).</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with teriflunomide in one or more subsets of the paediatric population in multiple sclerosis (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Median time to reach maximum plasma concentrations occurs between 1 to 4 hours post-dose following repeated oral administration of teriflunomide, with high bioavailability (approximately 100%).</p><p>Food does not have a clinically relevant effect on teriflunomide pharmacokinetics.</p><p>From the mean predicted pharmacokinetic parameters calculated from the population pharmacokinetic (PopPK) analysis using data from healthy volunteers and MS patients, there is a slow approach to steady-state concentration (i.e., approximately 100 days (3.5 months) to attain 95% of steady-state concentrations) and the estimated AUC accumulation ratio is approximately 34-fold.</p><p><strong><u>Distribution</u></strong></p><p>Teriflunomide is extensively bound to plasma protein (&gt;99%), probably albumin and is mainly distributed in plasma. The volume of distribution is 11 l after a single intravenous (IV) administration. However, this is most likely an underestimation since extensive organ distribution was observed in rats.</p><p><strong><u>Biotransformation</u></strong></p><p>Teriflunomide is moderately metabolised and is the only component detected in plasma. The primary biotransformation pathway for teriflunomide is hydrolysis with oxidation being a minor pathway. Secondary pathways involve oxidation, N-acetylation and sulfate conjugation.</p><p><strong><u>Elimination</u></strong></p><p>Teriflunomide is excreted in the gastrointestinal tract mainly through the bile as unchanged medicinal active substance and most likely by direct secretion. Teriflunomide is a substrate of the efflux transporter BCRP, which could be involved in direct secretion. Over 21 days, 60.1% of the administered dose is excreted via feces (37.5%) and urine (22.6%). After the rapid elimination procedure with cholestyramine, an additional 23.1% was recovered (mostly in feces). Based on individual prediction of pharmacokinetic parameters using the PopPK model of teriflunomide in healthy volunteers and MS patients, median t1/2z&nbsp;was approximately 19 days after repeated doses of 14 mg. After a single intravenous administration, the total body clearance of teriflunomide is 30.5 ml/h.</p><p><strong>Accelerated elimination procedure: cholestyramine and activated charcoal</strong></p><p>The elimination of teriflunomide from the circulation can be accelerated by administration of cholestyramine or activated charcoal, presumably by interrupting the reabsorption processes at the intestinal level. Teriflunomide concentrations measured during an 11-day procedure to accelerate teriflunomide elimination with either 8 g cholestyramine three times a day, 4 g cholestyramine three times a day or 50 g activated charcoal twice a day following cessation of teriflunomide treatment have shown that these regimens were effective in accelerating teriflunomide elimination, leading to more than 98% decrease in teriflunomide plasma concentrations, with cholestyramine being faster than charcoal. Following discontinuation of teriflunomide and the administration of cholestyramine 8 g three times a day, the plasma concentration of teriflunomide is reduced 52% at the end of day 1, 91% at the end of day 3, 99.2% at the end of day 7, and 99.9% at the completion of day 11. The choice between the 3 elimination procedures should depend on the patient&#39;s tolerability. If cholestyramine 8 g three times a day is not well-tolerated, cholestyramine 4 g three times a day can be used. Alternatively, activated charcoal may also be used (the 11 days do not need to be consecutive unless there is a need to lower teriflunomide plasma concentration rapidly).</p><p><strong><u>Linearity/non-linearity</u></strong></p><p>Systemic exposure increases in a dose proportional manner after oral administration teriflunomide from 7 to 14 mg.</p><p><strong><u>Characteristics in specific groups of patients</u></strong></p><p><strong>Gender and elderly</strong></p><p>Several sources of intrinsic variability were identified in healthy subjects and MS patients based on the PopPK analysis: age, body weight, gender, race, and albumin and bilirubin levels. Nevertheless, their impact remains limited (&le;31%).</p><p><strong><u>Hepatic impairment</u></strong></p><p>Mild and moderate hepatic impairment had no impact on the pharmacokinetic of teriflunomide. Therefore no dose adjustment is anticipated in mild and moderate hepatic-impaired patients. However, teriflunomide is contraindicated in patients with severe hepatic impairment (see sections 4.2 and 4.3).</p><p><strong><u>Renal impairment</u></strong></p><p>Severe renal impairment had no impact on the pharmacokinetic of teriflunomide. Therefore no dose adjustment is anticipated in mild, moderate and severe renal-impaired patients.</p><p><strong><u>Paediatric population</u></strong></p><p>In paediatric patients with body weight &gt;40 kg treated with 14 mg once daily, steady state exposures were in the range observed in adult patients treated with the same dosing regimen.</p><p>In paediatric patients with body weight &le;40 kg treatment with 7 mg once daily (based on limited clinical data and simulations) led to steady state exposures in the range observed in adult patients treated with 14 mg once daily.</p><p>Observed steady state trough concentrations were highly variable between individuals, as observed for adult MS patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated oral administration of teriflunomide to mice, rats and dogs for up to 3, 6, and 12 months, respectively, revealed that the major targets of toxicity were the bone marrow, lymphoid organs, oral cavity/ gastro intestinal tract, reproductive organs, and pancreas. Evidence of an oxidative effect on red blood cells was also observed. Anemia, decreased platelet counts and effects on the immune system, including leukopenia, lymphopenia and secondary infections, were related to the effects on the bone marrow and/or lymphoid organs. The majority of effects reflect the basic mode of action of the compound (inhibition of dividing cells). Animals are more sensitive to the pharmacology, and therefore toxicity, of teriflunomide than humans. As a result, toxicity in animals was found at exposures equivalent or below human therapeutic levels.</p><p>Teriflunomide was not mutagenic&nbsp;<em>in vitro</em>&nbsp;or clastogenic&nbsp;<em>in vivo</em>. Clastogenicity observed&nbsp;<em>in vitro</em>&nbsp;was considered to be an indirect effect related to nucleotide pool imbalance resulting from the pharmacology of DHO-DH inhibition. The minor metabolite TFMA (4-trifluoromethylaniline) caused mutagenicity and clastogenicity&nbsp;<em>in vitro</em>&nbsp;but not&nbsp;<em>in vivo</em>.</p><p>No evidence of carcinogenicity was observed in rats and mice.</p><p>Fertility was unaffected in rats despite adverse effects of teriflunomide on male reproductive organs, including reduced sperm count. There were no external malformations in the offspring of male rats administered teriflunomide prior to mating with untreated female rats. Teriflunomide was embryotoxic and teratogenic in rats and rabbits at doses in the human therapeutic range. Adverse effects on the offspring were also seen when teriflunomide was administered to pregnant rats during gestation and lactation. The risk of male-mediated embryo-fetal toxicity through teriflunomide treatment is considered low. The estimated female plasma exposure via the semen of a treated patient is expected to be 100 times lower than the plasma exposure after 14 mg of oral teriflunomide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, maize starch, hydroxy propyl cellulose, microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, Opadry Yellow (HPMC 2910 / Hypromellose, Titanium Dioxide, Macrogol/ PEG, Iron oxide Yellow, Iron oxide Red).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Myteb<sup>&reg; </sup>14mg tablets </strong>are Light yellow color round shaped biconvex film coated tablets debossed with &ldquo;A&rdquo; on one side and &ldquo;14&rdquo;on the other side, presented in Aluminum foil OPA/Alu/PVC blisters, intended for oral use.</p><p><strong>Pack Size:</strong></p><p>28 Film Coated Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Med City Pharma-KSA.
Tel: 00966920003288
Fax: 00966126358138
Mobile: 00966555786968
P.O .Box: 42512 - Jeddah 21551
E-mail: MD.admin@Axantia.com
Manufactured by: 
Aizant Drug Research Solutions Pvt. Ltd - India.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>